Stocks

Headlines

Regeneron Pharmaceuticals Inc. Scores 71% on Value Model

Regeneron Pharmaceuticals Inc. shows strong fundamentals with a 71% score using Benjamin Graham's Value Investor model. The stock exhibits strengths in multiple areas but struggles with P/E and price/book ratios.

Date: 
AI Rating:   6
Analysis of Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. has achieved a rating of 71% according to the Value Investor model based on Benjamin Graham's strategy. This methodology emphasizes stocks with low P/B and P/E ratios, coupled with low debt and substantial long-term earnings growth.

Earnings Per Share (EPS)
The report mentions strong long-term EPS growth, marking a positive aspect of the company's financial health. This indicates robust earnings potential over time, which could attract investors looking for sustainable growth.

Revenue Growth
The report states that the company meets expectations in sales, indicating consistent revenue growth. This could enhance investor confidence, as revenue is a critical factor in determining a company's performance.

Net Income
Net income figures are not specifically provided in the report. Therefore, no assessment can be made regarding its impact on investor sentiment.

Profit Margins
The report does not mention specifics regarding gross, operating, or net profit margins. Without this key information, it's challenging to assess how effectively the company converts sales into actual profit.

Free Cash Flow (FCF)
No references to free cash flow are included in the text, so this cannot be evaluated for its potential impact on the stock price.

Return on Equity (ROE)
Return on equity is also absent from the report, leaving a gap in understanding how efficiently the company is utilizing shareholder equity.

Despite some shortcomings in specific areas like P/E and price/book ratios—where it has failed—Regeneron has shown strong fundamentals and earnings growth that can significantly influence investor sentiment positively. However, the red flags in valuation ratios could temper enthusiasm, leading to a careful consideration by potential investors.
Stocks:  REGN